Related Experiment Video
Updated: May 17, 2025

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Cyp51A Dysfunction Leads to Higher Susceptibility to Azoles Including Fluconazole in Aspergillus fumigatus
Hidetaka Majima1, Teppei Arai1, Naoto Maruguchi1
1Medical Mycology Research Center, Chiba University, Chiba, Japan.
Background:
Azoles target Cyp51A and Cyp51B in Aspergillus fumigatus. Mutations in cyp51A are known as the primary mechanisms of azole resistance. However, not all of them cause azole resistance. Among them, mutations related to improved susceptibility have not been reported so far. We found that two isolates that carry frameshift or nonsense mutations in cyp51A are more susceptible to azoles, even to fluconazole (FLCZ) (IC50: frameshift, 32 μg/mL; nonsense, 32 μg/mL) compared to other azole-susceptible strains (IC50: > 256 μg/mL).
Objectives:
We investigated the contribution of these two mutations to azole sensitivity and their effect on Cyp51A functions.
Methods:
We transformed an experimental strain, AfS35, by replacing cyp51AWT with each of the mutated cyp51A and measured its MICs to azoles. We also evaluated the functions of mutated Cyp51A after suppression of Cyp51B, based on the notion that Cyp51A and Cyp51B complement each other.
Results:
Induction of mutated cyp51A in AfS35 led to higher susceptibility to FLCZ (IC50: frameshift, 32-64 μg/mL; nonsense, 32 μg/mL). Transformants carrying either of the mutated cyp51A could not survive when cyp51B was suppressed, indicating that these cyp51A mutations result in Cyp51A dysfunction. Furthermore, a cyp51A-deleted mutant strain also showed increased susceptibility to FLCZ (IC50: 32 μg/mL), similar to cyp51A dysfunctional strains, while a cyp51B-deleted mutant strain showed unchanged susceptibility (IC50: > 256 μg/mL) from AfS35.
Conclusions:
It was suggested that FLCZ can inhibit Cyp51B rather than Cyp51A and that this unequal inhibition leads to higher azole susceptibility of the two isolates harbouring Cyp51A dysfunction.
Insights
Novel frameshift or nonsense mutations in Aspergillus fumigatus cyp51A increase susceptibility to fluconazole (FLCZ). These mutations cause Cyp51A dysfunction, suggesting FLCZ targets Cyp51B more effectively.
Area of Science:
- Medical Mycology
- Antifungal Drug Resistance
- Molecular Biology
Background:
- Azoles are key antifungal agents targeting Cyp51A and Cyp51B in Aspergillus fumigatus.
- While cyp51A mutations are linked to azole resistance, some may alter susceptibility unexpectedly.
- Two isolates with frameshift or nonsense mutations in cyp51A exhibited increased susceptibility to fluconazole (FLCZ).
Purpose of the Study:
- To investigate the impact of specific cyp51A mutations on azole sensitivity.
- To determine the functional consequences of these mutations on Cyp51A activity.
Main Methods:
- Experimental transformation of Aspergillus fumigatus strain AfS35 with mutated cyp51A alleles.
- Measurement of minimum inhibitory concentrations (MICs) to azoles for transformant strains.
- Evaluation of mutated Cyp51A function under conditions of Cyp51B suppression.
Main Results:
- Transformants expressing mutated cyp51A showed significantly higher susceptibility to FLCZ (IC50: 32-64 μg/mL).
- These cyp51A mutations led to Cyp51A dysfunction, as evidenced by non-viability when Cyp51B was suppressed.
- A cyp51A-deleted strain also displayed increased FLCZ susceptibility, unlike a cyp51B-deleted strain.
Conclusions:
- The findings suggest that FLCZ may preferentially inhibit Cyp51B over Cyp51A.
- Cyp51A dysfunction, rather than direct azole interaction with mutated Cyp51A, underlies the observed increased azole susceptibility.
- This highlights a complex interplay between target enzymes and drug action in azole resistance and susceptibility.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...

